CA2967951C — Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Assigned to Array Biopharma Inc · Expires 2023-11-07 · 3y expired
What this patent protects
A crystalline form of (S)-N-(5-((R-2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide, pharmaceutic al compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflamma…
USPTO Abstract
A crystalline form of (S)-N-(5-((R-2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide, pharmaceutic al compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the crystalline form comprises a stable polymorph of (S)-N-5-(R-2-(2,5-di fluorophenyl)pyrrollidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carbox amide hydrogen sulfate (I-HS). The present invention is further directed to a process for the preparation of the crystalline form. (see formula I-HS)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.